Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
- Conditions
- ObesityAlzheimer's Disease
- Interventions
- Procedure: Blood sample
- Registration Number
- NCT02868905
- Lead Sponsor
- Central Hospital, Nancy, France
- Brief Summary
The purpose of this study is to compare average methylation of epigenetic markers on genomic DNA and some genes (APP, BACE, LRP, SorL1) involved in cerebral amyloid homeostasis:
* Of obese young adults and healthy young adults
* Of obese young adults and individuals affected by Alzheimer's disease (AD) having been obese at young adult age (\<50 years old) or individuals affected by Alzheimer's disease (AD) having never been obese.
The secondary purpose is to determine if there is an association between the frequency of these epigenetic markers and elements associated to the metabolic syndrome (lipidic and glycemic analysis, leptinemia, inflammation markers) and clinical ones (visceral fat mass, body mass index) in young adults.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 160
Group 1:
- 18-50 year old women, age- (10 years) and sociocultural-matched with group 2
- Non obese and never been obese
- 18.5 < BMI < 25
- Folstein MMS > 27
- Informed consent
- Affiliation to social security plan
Group 2:
- 18-50 year old women, age- (10 years) and sociocultural-matched with group 1
- Waist size > 88cm
- 30 < BMI < 45
- Insulin-resistant patients (Insulin resistance index, HOMA-IR > 3.8)
- Obesity onset during childhood (pre-puberty period)
- Folstein MMS > 27
- Informed consent
- Affiliation to social security plan
Group 3:
- >60 year old women, age- (10 years) matched with group 4
- No obesity history (18.5 ≤ BMI < 25 at adult age)
- Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic process according to new recommendations of 2011 of National Institute on Aging and Alzheimer's Association on diagnostic guidelines for Alzheimer's disease
- 15< Folstein MMS ≤ 26
- Informed consent
- Affiliation to social security plan
Group 4:
- >60 year old women, age- (10 years) matched with group 3
- Obesity history (BMI > 30 at least one time at adult age)
- Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic process according to new recommendations of 2011 of National Institute on Aging and Alzheimer's Association on diagnostic guidelines for Alzheimer's disease
- 15 < Folstein MMS ≤ 26
- Informed consent
- Affiliation to social security plan
Group 1:
- <18
- Patient under guardianship, curatorship or judicial protection
- Folate supplementation
- Diabetic or glucose intolerant subjects
- Present participation to another study with neuropsychological evaluation and/or drug administration
- Pregnant women
Groups 2,3 and 4:
- <18
- Patient under guardianship, curatorship or judicial protection
- Folate supplementation
- Present participation to another study with neuropsychological evaluation and/or drug administration
Group 2:
- Pregnant women
Group 4:
- Obese or overweight patients (BMI>25)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control group Blood sample Control group Obese group Blood sample Obese group Non-obese AD group Blood sample Non-obese AD groups Obese AD group Blood sample Obese AD group
- Primary Outcome Measures
Name Time Method Methylation of CpG islands in genomic DNA and in 4 target genes involved in AD (APP, SorLA/LR11, BACE1, LRP) in obese and AD subjects day 0
- Secondary Outcome Measures
Name Time Method body mass index day 0 visceral fat mass level day 0 leptinemia by ELISA day 0 insulinemia by ELISA day 0 glycemia day 0 triglyceridemia day 0 HDL cholesterol level in blood day 0 Reactive C protein level in blood day 0
Trial Locations
- Locations (1)
CHRU de Nancy
🇫🇷Nancy, France